Data di Pubblicazione:
2019
Citazione:
Risk of breast cancer in patients with lymphangioleiomyomatosis / O. Nunez, B.G. Baldi, E. Radzikowska, C.R.R. Carvalho, C. Herranz, M. Sobiecka, O. Torre, S. Harari, M.A.M.H. Vergeer, J. Kolbe, M. Pollan, M.A. Pujana. - In: CANCER EPIDEMIOLOGY. - ISSN 1877-7821. - 61(2019), pp. 154-156. [10.1016/j.canep.2019.06.004]
Abstract:
Lymphangioleiomyomatosis (LAM) is a rare metastasizing pulmonary disease that shares some clinical, cellular, and molecular similarities with metastatic breast cancer to lung. LAM cells have been identified circulating in various body fluids of patients and, intriguingly, diverse evidence indicates that these cells may originate from a different organ to the lung. Following on from these observations, we hypothesized the existence of a common risk basis between LAM and breast cancer, and suggested increased risk of breast cancer among LAM patients. Here, by studying two additional LAM cohorts with more detailed epidemiological, life-style, and disease-related data, we show consistent results; a potential excess of estrogen-receptor-positive young breast cancer cases in LAM. This observation further suggests the need of prospective studies to precisely assess the association between both diseases.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Breast cancer; Estrogen receptor; Incidence; Lymphangioleiomyomatosis; Metastasis; mTOR; Breast Neoplasms; Female; Humans; Lymphangioleiomyomatosis; Neoplasm Metastasis; Prospective Studies
Elenco autori:
O. Nunez, B.G. Baldi, E. Radzikowska, C.R.R. Carvalho, C. Herranz, M. Sobiecka, O. Torre, S. Harari, M.A.M.H. Vergeer, J. Kolbe, M. Pollan, M.A. Pujana
Link alla scheda completa: